Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03114462 · ClinicalTrials.gov registry record · Phase 1

Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

A Phase 1 study of Malignant Neoplasms of Respiratory and Intrathoracic Organs and Squamous Cell Carcinoma of the Larynx, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
11
Enrollment target
1
Study location

NCT03114462 is a Phase 1 study of Malignant Neoplasms of Respiratory and Intrathoracic Organs and Squamous Cell Carcinoma of the Larynx that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 11 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03114462, a Phase 1 study of Malignant Neoplasms of Respiratory and Intrathoracic Organs and Squamous Cell Carcinoma of the Larynx, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
11 participants
Enrollment target
1
Study location

Study Summary

To find the highest tolerable dose of stereotactic hypofractionated radioablation (HYDRA) radiation that can be given to patients with laryngeal cancer. The safety of this radiation will also be studied.

Interventions

  • BEHAVIORAL Questionnaires
  • RADIATION Stereotactic Hypofractionated Radioablation

Study Locations (1)

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2017-08-09
Est. Completion 2027-06-01
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT03114462

The ClinicalTrials.gov registry entry for NCT03114462 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Malignant Neoplasms of Respiratory and Intrathoracic Organs appearing as the primary indexed condition, and to 2 interventions - of which Questionnaires is the first listed.

NCT03114462 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT03114462 about?

NCT03114462 is a clinical study titled "Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer". To find the highest tolerable dose of stereotactic hypofractionated radioablation (HYDRA) radiation that can be given to patients with laryngeal cancer. The safety of this radiation will also be studied.

What is the current status of trial NCT03114462?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2017-08-09. Estimated completion is 2027-06-01.

What conditions does trial NCT03114462 study?

This clinical trial studies the following conditions: Malignant Neoplasms of Respiratory and Intrathoracic Organs, Squamous Cell Carcinoma of the Larynx.

What interventions are being tested in trial NCT03114462?

The interventions under investigation include: Questionnaires (BEHAVIORAL), Stereotactic Hypofractionated Radioablation (RADIATION).

Who is sponsoring clinical trial NCT03114462?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03114462 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Neoplasms of Respiratory and Intrathoracic Organs

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.